Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

RU-486 Lower-Dose, Home-Administered Misoprostol Being Evaluated

Executive Summary

The Population Council is planning a trial to demonstrate that a 200 mg dose of the abortifacient Mifeprex is effective and that the misoprostol component of the regimen can be safely used at home.

You may also be interested in...



Pharmacia VP Friedman Is Among PhRMA Favorites For FDA Commissioner

Pharmacia Senior VP Michael Friedman's recent letter to the New England Journal of Medicine regarding the use of Cytotec (misoprostol) in pregnant women should help continue his candidacy to return to FDA as commissioner.

Pharmacia Cytotec Use For Labor Induction Reaffirmed By ACOG

The American College of Obstetricians & Gynecologists is reaffirming its guidelines supporting the use of Pharmacia/Searle's Cytotec (misoprostol) for the induction of labor.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Latest Headlines
See All
UsernamePublicRestriction

Register

PS037339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel